• Ilixadencel Provokes Strong Response Against Kidney Cancer, Phase 1/2 Clinical Trial Shows
  • Generon’s A-337 Antibody Is Entering Phase 1 Trial as Treatment for Solid Tumors
  • Acceleron Discontinues Development of Dalantercept for Advanced Renal Cell Carcinoma Therapy
  • Radiotherapy Booster NBTXR3 Can Trigger Anti-Tumor Immune Responses, Studies Suggest
  • Trial of Tivozanib as Combo Therapy for Kidney Cancer Enters Phase 2 Stage
  • Varlilumab-Opdivo Combo Stabilizes or Shrinks Tumors in 80% of Solid-cancer Patients, Trial Shows
  • First Patient Dosed in Immunotherapy Combo Trial of Yervoy, Evofosfamide in Solid Tumors
  • Early Trial Data Supports Keytruda as Standalone Therapy for Advanced Stomach Cancers
  • OncoSec’s Metastatic Melanoma Therapy Candidate ImmunoPulse IL-12 Wins FDA Orphan Drug Status
  • NANT Cancer Vaccine Clinical Trial Plans Expanding to Include Multiple Cancers
  • Phase 1 Trial Results Show JTX-2011 was Well-tolerated in Advanced Solid Tumors
  • Early Data from Immunotherapy Studies in Advanced Cancer Patient Show Promise, Parker Institute Reports